- Home
- PLRX vs GDL Comparison
PLRX vs GDL Comparison
Compare PLRX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLRX | GDL |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 94.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | GDL |
|---|---|---|
| Price | $1.31 | $8.39 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $3.79 | N/A |
| AVG Volume (30 Days) | ★ 945.1K | 11.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $7.65 |
| 52 Week High | $13.46 | $8.13 |
Technical Indicators
Market Signals| Indicator | PLRX | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 42.53 |
| Support Level | $1.20 | $8.35 |
| Resistance Level | $1.36 | $8.47 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 64.71 | 26.53 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.